Modern rheumatology
-
Modern rheumatology · Nov 2019
Predictors of presarcopenia in community-dwelling older adults: A 5-year longitudinal study.
Objectives: Sarcopenia is an aging-induced decrease in muscle mass that increases frailty and fall in elderly people. Presarcopenia corresponds to the preliminary stage of sarcopenia. The purpose of this prospective study is to examine predictors of presarcopenia in health screening. ⋯ BMI, grip strength, BMD, back muscle strength, and osteoporosis deteriorated significantly more in the pre-sarcopenia group (n = 33) compared with controls (n = 91; no presarcopenia in 2015). In multivariate analysis, osteoporosis (OR 3.12, 95% CI 1.07-9.09; p < .05) was significantly associated with presarcopenia after 5 years. Conclusions: Establishment of risk factors for future pre-sarcopenia may allow development of evidence-based prevention strategies for this condition.
-
Modern rheumatology · Sep 2019
Randomized Controlled TrialEfficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Objectives: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We investigated concomitant methotrexate (MTX) dose on tofacitinib efficacy/safety in Japanese RA patients. Methods: This post hoc analysis pooled data from a 3-month phase 2 study (NCT00603512) and a 24-month phase 3 study (NCT00847613). ⋯ AE rates with low-dose/high-dose MTX were: placebo, 28.6%/52.9%; tofacitinib low-dose, 50.0%/66.7%; 5 mg BID, 56.5%/64.3%; 10 mg BID, 73.8%/67.7%. Conclusion: Tofacitinib efficacy in Japanese RA patients may be unaffected by background MTX dose. AE rates with low-dose versus high-dose MTX were lower with placebo, tofacitinib low-dose or 5 mg BID, but not 10 mg BID, with no apparent differences across system organ class/laboratory parameters.
-
Modern rheumatology · Jul 2019
Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis.
Objectives: Sarcopenia is characterized by loss of muscle strength and mass, leading to falls and adverse health outcomes. Our aim was to determine the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) and to identify factors associated with sarcopenia in these patients. Methods: A cross-sectional study of 388 consecutive women with RA was conducted, assessing muscle mass and strength, and walking speed. ⋯ Age, RA duration, Steinbrocker's stage, the high Mini-Nutritional Assessment-Short Form score and the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) were independent factors associated with sarcopenia. Conclusion: We confirmed that sarcopenia develops in a significant proportion of patients with RA. Age, longer disease duration, joint destruction and malnutrition were positively associated with sarcopenia, with the use of bDMARDs being negatively associated.
-
Modern rheumatology · May 2019
Randomized Controlled Trial Multicenter StudyEfficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
To assess the efficacy and safety of intravenous (IV) belimumab plus standard systemic lupus erythematosus (SLE) therapy standard of care (SoC) in Japanese patients with SLE. ⋯ In Japanese patients with SLE, belimumab improved disease activity, with efficacy and safety results similar and consistent to the pivotal Phase 3 trials, suggesting that belimumab is a potential treatment option in this population.
-
Modern rheumatology · May 2019
Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term. ⋯ MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD.